Related Experiment Video

Updated: Aug 16, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

[Immunotherapy based on dendritic cells: from experimentation to clinical development]

M Goldman1

  • 1Laboratoire d'immunologie expérimentale ULB, Bâtiment G/E, 808, route de Lennik CP 615, 1070, Bruxelles, Belgique. mgoldman@ulb.ac.be <mgoldman@ulb.ac.be>

Pathologie-Biologie
|June 13, 2003
PubMed

Insights

Researchers explored dendritic cell (DC) immunotherapy for cancer, focusing on generating novel human dendritic cells and enhancing their anti-cancer potential for clinical applications.

Area of Science:

  • Immunotherapy
  • Cellular immunology
  • Cancer research

Context:

  • Dendritic cell (DC)-based cancer immunotherapy shows promise in preclinical studies.
  • Translating DC immunotherapy to human applications requires addressing challenges in DC generation, functional analysis, and patient immunomonitoring.
  • Current research focuses on optimizing DC potential for clinical use.

Purpose:

  • To investigate the cytotoxic activity of dendritic cells.
  • To generate a novel population of human dendritic cells from monocytes using Interleukin-3 (IL-3) and Interferon-beta (IFN-beta).
  • To enhance the immunostimulatory properties of dendritic cells through Fas-ligand overexpression or adjuvants that promote DC/gamma-delta T cell interactions.

Summary:

  • This study focuses on key aspects of dendritic cell (DC) immunotherapy for cancer.
  • It details the investigation into DC cytotoxic activity.
  • A novel method for generating human dendritic cells from monocytes using IL-3 and IFN-beta is presented, alongside strategies to optimize their immunostimulatory functions, including Fas-ligand overexpression and adjuvants for enhanced DC/gamma-delta T cell interaction.

Impact:

  • Provides insights into optimizing dendritic cell generation and function for human cancer immunotherapy.
  • Contributes to the development of more effective DC-based cancer treatments.
  • Highlights strategies for improving DC immunogenicity and T cell engagement in cancer patients.

More Related Videos

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...